AMRYT PHARMA PLC (LON:AMYT)

Amryt Pharma plc is a UK-based biopharmaceutical company, which develops and delivers innovative commercialised treatments to help the patients with rare and orphan diseases improve their lives. It was founded in the year 2004, and its headquarters are situated in London. The company is listed on the Alternative Investment Market (AIM) of the London Stock Exchange, and complies with the UK City Code on Takeovers and Mergers. Its shares are also traded on the NASDAQ Global Select Market.

The aim of the company is to quickly and responsibly use its expertise and in-depth knowledge to create new solutions for people living in debilitating conditions. The company, with its significant development pipeline and growing commercial business, believes in its core principles of ethics and integrity, and thus creates transformative treatments for the people in need across the globe. The product portfolio of the company consists of specialist therapies, which include Juxtapid/ Lojuxta (Lomitapide), Myalept / Myalepta (Metreleptin), Oleogel-S10 (AP101), and AP103 (Gene therapy). The pipeline of the company consists of products that target multiple orphan diseases, and some products are still on clinical trials and haven’t been approved yet, such as Lomitapide and AP101 (Oleogel S-10). The company employs a skilled and highly qualified workforce of healthcare professionals, and it partners with nurses, pharmacists, and clinicians etc. to support the healthcare professionals in delivering effective medical treatment to the patients with the most challenging and rare conditions.

With the commitment to undertake a high-quality meticulous research, the company aims at gathering the necessary evidence related to the efficacy of its treatments and medicines, and use this evidence to increase the confidence of clinicians to treat the patients in need, while ensuring timely access to medicines. It offers solutions for rare conditions, such as Homozygous Familial Hypercholesterolaemia (HoFH), Lipodystrophy, and Epidermolysis Bullosa or EB, in addition to gene therapy solutions.

Amryt Pharma plc follows a well-defined framework of corporate governance and aligns itself with the Quoted Companies Alliance (QCA) Corporate Governance Code. The board of the company has set up separate committees for audit, remuneration, compliance and nomination. It has an ethical code of conduct, known as Code of Business Conduct, for running its business operations and promotes a culture of trust, transparency, and accountability. Maintaining privacy and safeguarding personal information of patients is given key priority. It also follows strict anti-bribery and anti-corruption policies. Apart from fulfilling all its corporate responsibilities, the company also fulfils its environmental and social responsibilities. It complies with international best practices and guidelines to create a sustainable and responsible business. It aims to minimize the impact of its business activities on the environment and create long-term value for the business as well as the patients, caregivers, and the wider community.